Comments
Loading...

Apellis Pharmaceuticals Analyst Ratings

APLSNASDAQ
Logo brought to you by Benzinga Data
$18.83
-0.43-2.23%
At close: -
$18.83
0.000.00%
After Hours: Jun 13, 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$106.00
Lowest Price Target1
$18.00
Consensus Price Target1
$43.35

Apellis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:APLS | Benzinga

Apellis Pharmaceuticals Inc has a consensus price target of $43.35 based on the ratings of 21 analysts. The high is $106 issued by Raymond James on January 11, 2024. The low is $18 issued by RBC Capital on May 8, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, Citigroup, and Mizuho on June 2, 2025, May 22, 2025, and May 14, 2025, respectively. With an average price target of $30 between Wells Fargo, Citigroup, and Mizuho, there's an implied 59.32% upside for Apellis Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
2
2
Mar
1
Apr
4
3
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.2
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wells Fargo
Citigroup
Mizuho
Raymond James
B of A Securities

1calculated from analyst ratings

Analyst Ratings for Apellis Pharmaceuticals

Buy NowGet Alert
06/02/2025Buy Now54.01%Wells Fargo
Derek Archila61%
$26 → $29MaintainsEqual-WeightGet Alert
05/22/2025Buy Now117.74%Citigroup
Yigal Nochomovitz54%
$49 → $41MaintainsBuyGet Alert
05/14/2025Buy Now6.21%Mizuho
Graig Suvannavejh52%
$30 → $20MaintainsNeutralGet Alert
05/09/2025Buy Now176.16%Raymond James
Ryan Deschner76%
$75 → $52DowngradeStrong Buy → OutperformGet Alert
05/09/2025Buy Now22.15%B of A Securities
Tazeen Ahmad56%
$41 → $23DowngradeBuy → NeutralGet Alert
05/08/2025Buy Now-4.41%RBC Capital
Luca Issi46%
$21 → $18MaintainsSector PerformGet Alert
05/08/2025Buy Now6.21%Scotiabank
Greg Harrison48%
$28 → $20MaintainsSector PerformGet Alert
05/08/2025Buy Now38.08%Wells Fargo
Derek Archila61%
$30 → $26MaintainsEqual-WeightGet Alert
05/08/2025Buy Now149.6%Baird
Colleen Kusy36%
$55 → $47MaintainsOutperformGet Alert
05/07/2025Buy Now54.01%Needham
Joseph Stringer62%
$40 → $29MaintainsBuyGet Alert
04/29/2025Buy Now133.67%Cantor Fitzgerald
Eliana Merle49%
→ $44Initiates → OverweightGet Alert
04/21/2025Buy Now11.52%RBC Capital
Luca Issi46%
$24 → $21MaintainsSector PerformGet Alert
04/02/2025Buy Now64.63%Scotiabank
Greg Harrison48%
$30 → $31MaintainsSector PerformGet Alert
03/04/2025Buy Now186.78%JP Morgan
Anupam Rama60%
$50 → $54MaintainsOverweightGet Alert
03/03/2025Buy Now32.77%RBC Capital
Luca Issi46%
$26 → $25MaintainsSector PerformGet Alert
03/03/2025Buy Now69.94%Goldman Sachs
Salveen Richter52%
$36 → $32MaintainsNeutralGet Alert
03/03/2025Buy Now54.01%Wedbush
Laura Chico51%
$30 → $29MaintainsNeutralGet Alert
03/03/2025Buy Now202.71%HC Wainwright & Co.
Douglas Tsao53%
$57 → $57ReiteratesBuy → BuyGet Alert
02/13/2025Buy Now202.71%HC Wainwright & Co.
Douglas Tsao53%
$57 → $57ReiteratesBuy → BuyGet Alert
01/29/2025Buy Now38.08%RBC Capital
Luca Issi46%
$26 → $26MaintainsSector PerformGet Alert
01/21/2025Buy Now38.08%RBC Capital
Luca Issi46%
$26 → $26ReiteratesSector Perform → Sector PerformGet Alert
01/14/2025Buy Now202.71%HC Wainwright & Co.
Douglas Tsao53%
$57 → $57ReiteratesBuy → BuyGet Alert
12/17/2024Buy Now91.18%Goldman Sachs
Salveen Richter52%
→ $36DowngradeBuy → NeutralGet Alert
11/21/2024Buy Now64.63%Morgan Stanley
Judah Frommer65%
→ $31Initiates → Equal-WeightGet Alert
11/07/2024Buy Now192.09%Baird
Colleen Kusy36%
$92 → $55MaintainsOutperformGet Alert
11/06/2024Buy Now170.84%Citigroup
Yigal Nochomovitz54%
$63 → $51MaintainsBuyGet Alert
11/06/2024Buy Now91.18%Goldman Sachs
Salveen Richter52%
$71 → $36MaintainsBuyGet Alert
11/06/2024Buy Now27.46%RBC Capital
Luca Issi46%
$25 → $24MaintainsSector PerformGet Alert
11/06/2024Buy Now59.32%Scotiabank
Greg Harrison48%
$35 → $30MaintainsSector PerformGet Alert
11/06/2024Buy Now59.32%Wells Fargo
Derek Archila61%
$43 → $30MaintainsEqual-WeightGet Alert
11/06/2024Buy Now112.43%Oppenheimer
Justin Kim38%
$65 → $40MaintainsOutperformGet Alert
11/06/2024Buy Now69.94%Piper Sandler
Biren Amin41%
$40 → $32MaintainsNeutralGet Alert
11/06/2024Buy Now202.71%HC Wainwright & Co.
Douglas Tsao53%
$83 → $57MaintainsBuyGet Alert
11/06/2024Buy Now149.6%B of A Securities
Tazeen Ahmad56%
$61 → $47MaintainsBuyGet Alert
11/06/2024Buy Now218.64%Needham
Joseph Stringer62%
$85 → $60MaintainsBuyGet Alert
11/04/2024Buy Now32.77%RBC Capital
Luca Issi46%
$25 → $25ReiteratesSector Perform → Sector PerformGet Alert
10/24/2024Buy Now101.81%Mizuho
Graig Suvannavejh52%
$39 → $38MaintainsNeutralGet Alert
10/16/2024Buy Now85.87%Scotiabank
Greg Harrison48%
→ $35Initiates → Sector PerformGet Alert
10/16/2024Buy Now—William Blair
Lachlan Brown38%
—Initiates → OutperformGet Alert
09/24/2024Buy Now128.36%Wells Fargo
Derek Archila61%
$47 → $43MaintainsEqual-WeightGet Alert
09/23/2024Buy Now388.58%Baird
Colleen Kusy36%
$96 → $92MaintainsOutperformGet Alert
09/20/2024Buy Now107.12%Mizuho
Graig Suvannavejh52%
$42 → $39MaintainsNeutralGet Alert
09/20/2024Buy Now351.41%Needham
Joseph Stringer62%
$85 → $85ReiteratesBuy → BuyGet Alert
09/13/2024Buy Now202.71%JP Morgan
Anupam Rama60%
$64 → $57MaintainsOverweightGet Alert
08/13/2024Buy Now239.88%JP Morgan
Anupam Rama60%
$72 → $64MaintainsOverweightGet Alert
08/09/2024Buy Now340.79%UBS
Eliana Merle49%
$85 → $83MaintainsBuyGet Alert
08/09/2024Buy Now117.74%Wedbush
Laura Chico51%
$38 → $41MaintainsNeutralGet Alert
08/09/2024Buy Now292.99%Goldman Sachs
Salveen Richter52%
$66 → $74MaintainsBuyGet Alert
08/09/2024Buy Now409.82%Baird
Colleen Kusy36%
$86 → $96MaintainsOutperformGet Alert
08/09/2024Buy Now351.41%Needham
Joseph Stringer62%
$85 → $85ReiteratesBuy → BuyGet Alert
08/02/2024Buy Now340.79%HC Wainwright & Co.
Douglas Tsao53%
$92 → $83MaintainsBuyGet Alert
08/02/2024Buy Now250.5%Goldman Sachs
Salveen Richter52%
$77 → $66MaintainsBuyGet Alert
08/02/2024Buy Now351.41%Needham
Joseph Stringer62%
$85 → $85ReiteratesBuy → BuyGet Alert
07/31/2024Buy Now324.85%Jefferies
Akash Tewari42%
$80 → $80MaintainsBuyGet Alert
07/26/2024Buy Now356.72%Baird
Colleen Kusy36%
$100 → $86MaintainsOutperformGet Alert
07/23/2024Buy Now431.07%Baird
Colleen Kusy36%
$100 → $100MaintainsOutperformGet Alert
07/17/2024Buy Now308.92%Goldman Sachs
Salveen Richter52%
$90 → $77MaintainsBuyGet Alert
06/28/2024Buy Now431.07%Baird
Colleen Kusy36%
$100 → $100MaintainsOutperformGet Alert
05/31/2024Buy Now144.29%Piper Sandler
Biren Amin41%
→ $46Initiates → NeutralGet Alert
05/28/2024Buy Now388.58%HC Wainwright & Co.
Douglas Tsao53%
$92 → $92ReiteratesBuy → BuyGet Alert
05/23/2024Buy Now154.91%Wells Fargo
Derek Archila61%
$57 → $48MaintainsEqual-WeightGet Alert
05/08/2024Buy Now351.41%Needham
Joseph Stringer62%
$85 → $85ReiteratesBuy → BuyGet Alert
05/08/2024Buy Now218.64%Citigroup
Yigal Nochomovitz54%
$67 → $60MaintainsBuyGet Alert
05/08/2024Buy Now388.58%HC Wainwright & Co.
Douglas Tsao53%
→ $92ReiteratesBuy → BuyGet Alert
05/08/2024Buy Now351.41%UBS
Eliana Merle49%
$89 → $85MaintainsBuyGet Alert
04/29/2024Buy Now176.16%Mizuho
Graig Suvannavejh52%
$60 → $52MaintainsNeutralGet Alert
04/26/2024Buy Now388.58%HC Wainwright & Co.
Douglas Tsao53%
$92 → $92ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now351.41%Needham
Joseph Stringer62%
$85 → $85ReiteratesBuy → BuyGet Alert
04/17/2024Buy Now202.71%Wedbush
Laura Chico51%
$67 → $57MaintainsNeutralGet Alert
04/15/2024Buy Now388.58%HC Wainwright & Co.
Douglas Tsao53%
$92 → $92ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now351.41%Needham
Joseph Stringer62%
$85 → $85ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now218.64%Mizuho
Graig Suvannavejh52%
$60 → $60MaintainsNeutralGet Alert
03/06/2024Buy Now319.54%JP Morgan
Anupam Rama60%
$78 → $79MaintainsOverweightGet Alert
03/04/2024Buy Now372.65%UBS
Eliana Merle49%
$87 → $89MaintainsBuyGet Alert
02/28/2024Buy Now388.58%HC Wainwright & Co.
Douglas Tsao53%
$92 → $92ReiteratesBuy → BuyGet Alert
02/28/2024Buy Now255.82%Wedbush
Laura Chico51%
$60 → $67MaintainsNeutralGet Alert
02/16/2024Buy Now218.64%Mizuho
Graig Suvannavejh52%
$49 → $60MaintainsNeutralGet Alert
02/06/2024Buy Now330.16%Baird
Colleen Kusy36%
→ $81ReiteratesOutperform → OutperformGet Alert
02/05/2024Buy Now324.85%Jefferies
Akash Tewari42%
$68 → $80UpgradeHold → BuyGet Alert
01/30/2024Buy Now319.54%Oppenheimer
Justin Kim38%
$75 → $79MaintainsOutperformGet Alert
01/24/2024Buy Now298.3%Needham
Joseph Stringer62%
$70 → $75MaintainsBuyGet Alert
01/17/2024Buy Now330.16%Baird
Colleen Kusy36%
$71 → $81MaintainsOutperformGet Alert
01/17/2024Buy Now388.58%HC Wainwright & Co.
Douglas Tsao53%
$82 → $92MaintainsBuyGet Alert
01/12/2024Buy Now218.64%Wedbush
Laura Chico51%
$39 → $60MaintainsNeutralGet Alert
01/11/2024Buy Now462.93%Raymond James
Steven Seedhouse58%
$67 → $106MaintainsStrong BuyGet Alert
01/09/2024Buy Now377.96%Goldman Sachs
Salveen Richter52%
$65 → $90MaintainsBuyGet Alert
12/15/2023Buy Now255.82%Citigroup
Yigal Nochomovitz54%
$70 → $67MaintainsBuyGet Alert
12/15/2023Buy Now298.3%Oppenheimer
Justin Kim38%
$88 → $75MaintainsOutperformGet Alert
12/15/2023Buy Now255.82%Raymond James
Steven Seedhouse58%
$93 → $67MaintainsStrong BuyGet Alert
12/14/2023Buy Now197.4%Needham
Joseph Stringer62%
$63 → $56MaintainsBuyGet Alert
12/14/2023Buy Now186.78%Wells Fargo
Derek Archila61%
$67 → $54DowngradeOverweight → Equal-WeightGet Alert
12/05/2023Buy Now351.41%B of A Securities
Tazeen Ahmad56%
$52 → $85UpgradeNeutral → BuyGet Alert
11/09/2023Buy Now292.99%Goldman Sachs
Salveen Richter52%
→ $74Initiates → BuyGet Alert
11/02/2023Buy Now123.05%Mizuho
Graig Suvannavejh52%
→ $42Initiates → NeutralGet Alert
11/02/2023Buy Now393.89%Raymond James
Steven Seedhouse58%
$92 → $93MaintainsStrong BuyGet Alert
11/01/2023Buy Now234.57%Needham
Joseph Stringer62%
$60 → $63MaintainsBuyGet Alert
10/12/2023Buy Now144.29%B of A Securities
Tazeen Ahmad56%
$44 → $46MaintainsNeutralGet Alert
10/06/2023Buy Now271.75%Citigroup
Yigal Nochomovitz54%
$54 → $70MaintainsBuyGet Alert
10/06/2023Buy Now330.16%JP Morgan
Anupam Rama60%
$60 → $81UpgradeNeutral → OverweightGet Alert
10/06/2023Buy Now388.58%Raymond James
Steven Seedhouse58%
$89 → $92MaintainsStrong BuyGet Alert

FAQ

Q

What is the target price for Apellis Pharmaceuticals (APLS) stock?

A

The latest price target for Apellis Pharmaceuticals (NASDAQ:APLS) was reported by Wells Fargo on June 2, 2025. The analyst firm set a price target for $29.00 expecting APLS to rise to within 12 months (a possible 54.01% upside). 58 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Apellis Pharmaceuticals (APLS)?

A

The latest analyst rating for Apellis Pharmaceuticals (NASDAQ:APLS) was provided by Wells Fargo, and Apellis Pharmaceuticals maintained their equal-weight rating.

Q

When was the last upgrade for Apellis Pharmaceuticals (APLS)?

A

The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.

Q

When was the last downgrade for Apellis Pharmaceuticals (APLS)?

A

The last downgrade for Apellis Pharmaceuticals Inc happened on May 9, 2025 when Raymond James changed their price target from $75 to $52 for Apellis Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Apellis Pharmaceuticals (APLS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on June 2, 2025 so you should expect the next rating to be made available sometime around June 2, 2026.

Q

Is the Analyst Rating Apellis Pharmaceuticals (APLS) correct?

A

While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a maintained with a price target of $26.00 to $29.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $18.83, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch